These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 29127587)

  • 1. Copanlisib: First Global Approval.
    Markham A
    Drugs; 2017 Dec; 77(18):2057-2062. PubMed ID: 29127587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Matasar MJ; Capra M; Özcan M; Lv F; Li W; Yañez E; Sapunarova K; Lin T; Jin J; Jurczak W; Hamed A; Wang MC; Baker R; Bondarenko I; Zhang Q; Feng J; Geissler K; Lazaroiu M; Saydam G; Szomor Á; Bouabdallah K; Galiulin R; Uchida T; Soler LM; Cao A; Hiemeyer F; Mehra A; Childs BH; Shi Y; Zinzani PL
    Lancet Oncol; 2021 May; 22(5):678-689. PubMed ID: 33848462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
    Patnaik A; Appleman LJ; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Weiss GJ; Sachdev JC; Chadha M; Fulk M; Ejadi S; Mountz JM; Lotze MT; Toledo FG; Chu E; Jeffers M; Peña C; Xia C; Reif S; Genvresse I; Ramanathan RK
    Ann Oncol; 2016 Oct; 27(10):1928-40. PubMed ID: 27672108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Copanlisib for the treatment of adults with relapsed follicular lymphoma.
    Magagnoli M; Carlo-Stella C; Santoro A
    Expert Rev Clin Pharmacol; 2020 Aug; 13(8):813-823. PubMed ID: 32576028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
    Grunenberg A; Kaiser LM; Woelfle S; Schmelzle B; Viardot A; Möller P; Barth TFE; Muche R; Dreyhaupt J; Raderer M; Kiesewetter B; Buske C
    BMC Cancer; 2021 Jun; 21(1):749. PubMed ID: 34187401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
    Dreyling M; Morschhauser F; Bouabdallah K; Bron D; Cunningham D; Assouline SE; Verhoef G; Linton K; Thieblemont C; Vitolo U; Hiemeyer F; Giurescu M; Garcia-Vargas J; Gorbatchevsky I; Liu L; Koechert K; Peña C; Neves M; Childs BH; Zinzani PL
    Ann Oncol; 2017 Sep; 28(9):2169-2178. PubMed ID: 28633365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.
    Matasar MJ; Dreyling M; Leppä S; Santoro A; Pedersen M; Buvaylo V; Fletcher M; Childs BH; Zinzani PL
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e886-e894. PubMed ID: 34389273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma.
    Zinzani PL; Wang H; Feng J; Kim TM; Tao R; Zhang H; Fogliatto L; Maluquer Artigal C; Özcan M; Yanez E; Kim WS; Kirtbaya D; Kriachok I; Maciel F; Xue H; Bouabdallah K; Phelps C; Chaturvedi S; Weispfenning A; Morcos PN; Odongo F; Buvaylo V; Childs BH; Dreyling M; Matasar M; Ghione P
    Blood Adv; 2024 Sep; 8(18):4866-4876. PubMed ID: 39058951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma.
    Eltantawy A; Vallejos X; Sebea E; Evans K
    Ann Pharmacother; 2019 Sep; 53(9):954-958. PubMed ID: 30813760
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Marret G; Isambert N; Rezai K; Gal J; Saada-Bouzid E; Rolland F; Chausson M; Borcoman E; Alt M; Klijanienko J; Vansteene D; Guigay J; Kamal M; Bièche I; Le Tourneau C;
    Invest New Drugs; 2021 Dec; 39(6):1641-1648. PubMed ID: 34322775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copanlisib (Aliqopa) for relapsed follicular lymphoma.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):e74-e75. PubMed ID: 29667951
    [No Abstract]   [Full Text] [Related]  

  • 12. Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives.
    Munoz J; Follows GA; Nastoupil LJ
    Target Oncol; 2021 May; 16(3):295-308. PubMed ID: 33687623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
    Dreyling M; Santoro A; Mollica L; Leppä S; Follows G; Lenz G; Kim WS; Nagler A; Dimou M; Demeter J; Özcan M; Kosinova M; Bouabdallah K; Morschhauser F; Stevens DA; Trevarthen D; Munoz J; Rodrigues L; Hiemeyer F; Miriyala A; Garcia-Vargas J; Childs BH; Zinzani PL
    Am J Hematol; 2020 Apr; 95(4):362-371. PubMed ID: 31868245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Umbralisib: First Approval.
    Dhillon S; Keam SJ
    Drugs; 2021 May; 81(7):857-866. PubMed ID: 33797740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
    Krause G; Hassenrück F; Hallek M
    Drug Des Devel Ther; 2018; 12():2577-2590. PubMed ID: 30174412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copanlisib in the treatment of non-Hodgkin lymphoma.
    Narkhede M; Cheson BD
    Future Oncol; 2020 Sep; 16(26):1947-1955. PubMed ID: 32658557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
    Dreyling M; Santoro A; Mollica L; Leppä S; Follows GA; Lenz G; Kim WS; Nagler A; Panayiotidis P; Demeter J; Özcan M; Kosinova M; Bouabdallah K; Morschhauser F; Stevens DA; Trevarthen D; Giurescu M; Cupit L; Liu L; Köchert K; Seidel H; Peña C; Yin S; Hiemeyer F; Garcia-Vargas J; Childs BH; Zinzani PL
    J Clin Oncol; 2017 Dec; 35(35):3898-3905. PubMed ID: 28976790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma.
    Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 5):14-6. PubMed ID: 24852792
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.
    Cheson BD; O'Brien S; Ewer MS; Goncalves MD; Farooki A; Lenz G; Yu A; Fisher RI; Zinzani PL; Dreyling M
    Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):135-141. PubMed ID: 30584024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.